[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endocrine-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endocrine-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,75,101,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100352329","study-of-endocrine-related-conditions-and-physiology-100352329",false,"NCT03867448","Study of Endocrine-Related Conditions and Physiology","The Evaluation and Management of Endocrine-Related Conditions and Physiology","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all the following criteria:\n\n* Adult men and women age 18 years or older.\n* Known or suspected endocrine disorders requiring clinical screening, management and\u002For treatment and follow-up.\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n\nEXCLUSION CRITERIA:\n\n* Unstable participants and participants with severe organ failure, or those with a condition or medical treatment that may affect\u002Flimit the endocrine work-up and exhaust Clinical Center, IETP resources will be excluded if appropriate.\n* Inability of a subject to adhere to a proposed schedule of visits.\n* Inability to provide informed consent.","ALL","18 Years","90 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","Background:\n\nEndocrine disorders involve changes to glands that produce hormones. Hormones are released by these glands into the blood so they can direct the function of other tissues in the body. Researchers want to study people who may have endocrine disorders. They want to learn more about the conditions that affect endocrine glands.\n\nObjective:\n\nTo study adults with a variety of endocrine disorders for research and physician education.\n\nEligibility:\n\nAdults ages 18 and older who have an endocrine or metabolic-related disorder\n\nHealthy volunteers 18 and older\n\nDesign:\n\nParticipants will be screened with a review of their medical records.\n\nParticipants will have a physical exam and medical history.\n\nThe length of the study and the schedule will vary by participant. Tests may include:\n\nBlood and urine tests\n\nStool and saliva samples\n\nImaging studies: Participants will lie on a table while a machine takes pictures of the body. They may be injected with a substance to make their organs more visible in the pictures.\n\nTests of endocrine tissue function\n\nConsultation with other specialists\n\nSleep study\n\nMedical photographs\n\nParticipants may be treated for their endocrine disorder. This could include:\n\nSurgery. If tissue is removed during surgery, it may be studied.\n\nRadiation\n\nMedicine\n\nParticipants may have genetic testing. This will be done with a small amount of blood, cells from a cheek swab, or saliva.\n\nSponsoring Institution: National Institute of Digestive, Diabetes and Kidney Disease",[25],"Endocrine Disease",[27,28,29],"Adrenal Gland","Pituitary","Natural History","RECRUITING","2026-06-27",{"date":33,"type":34},"2026-06-30","ACTUAL",{"date":36,"type":34},"2019-03-27",{"date":38,"type":21},"2036-01-01",{"name":40,"class":41},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":42},"100057209","phase-1-diagnosis-of-pheochromocytoma-100057209","NCT00004847","Diagnosis of Pheochromocytoma","Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and Paraganglioma","* INCLUSION CRITERIA:\n\nPatients are eligible for inclusion in this study if they are adults or children of age 3 years old and up with known, sporadic or familial PHEO\u002FPGL, on the basis of one or more of the following:\n\n1. High levels of blood or urinary catecholamines, metanephrines, methoxytyramine or chromogranin A.\n2. Highly suspected presence of PHEO\u002FPGL based on imaging studies, even with normal biochemistry.\n3. Personal or family history of PHEO\u002FPGL or genetic pathogenic variants known to predispose individuals to develop PHEO\u002FPGL.\n\nSigned informed consent is required. The informed consent may be signed by the patient, parent\u002Fguardian in pediatric patients or legally authorized representative (LAR) in adults who lack-decision making capacity to consent to research participation.\n\nPatients must have an outside general practitioner or endocrinologist. Patients with metastatic disease must also have an outside oncologist.\n\nFamily Members of Patients Arm (Linkage Analysis)\n\nParticipants are eligible for inclusion in this study arm if they are:\n\n* Adult family members of patients enrolled in this study;\n* The index family member in this study has a suspected hereditary PHEO\u002FPGL based on previous genetic testing and other suspicious hereditory patterns such as family history of multiple individuals with PHEO\u002FPGL; early age of disease onset; multiplicity of primary tumors; recurrence, etc. and\n* Signed informed consent form is required\n\nEXCLUSION CRITERIA:\n\nPotential patients will be excluded on the basis of one or more of the following:\n\n1. Pregnant or breastfeeding women\n2. Severe cardiac dysfunction\n3. Currently on dialysis\n\nA pregnancy test is performed in women of childbearing age (up to age 55) as a screening after consenting. If a patient is found to have a positive pregnancy test, her participation in this protocol will be terminated. The patient can enroll or re-enroll in the protocol when she is no longer pregnant or breastfeeding.\n\nIn-person participating patients who are not willing to return to the NIH (e.g., after surgery or an initial evaluation) for more than 2 years may be removed from the protocol.\n\nSPECIFIC INCLUSION\u002FEXCLUSION CRITERIA FOR IMAGING STUDIES WITHIN OUR PROTOCOL:\n\nIn adult patients (Excludes Linkage Analysis Arm)\n\nImaging studies are not done in patients that have the following exclusion criteria:\n\n* Inability to lie still for the entire imaging time (e.g., cough, severe arthritis, etc.).\n* Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (e.g., severe claustrophobia, radiation phobia, etc.)\n* Any additional medical conditions, serious illness, or other extenuating circumstance that, in the opinion of the Principal Investigator, may significantly interfere with study compliance.\n\nIn pediatric patients:\n\nInclusion criteria for research PET imaging in children:\n\n* Children over 10 years old with very high suspicion of sporadic or familial PHEO\u002FPGL based on at least one of the following:\n\n  * The presence of new onset of symptoms typical of PHEO\u002FPGL such as hypertension or hypertensive episodes, sweating, headaches, pallor, palpitations, drug resistant hypertension, etc.\n  * Family history of PHEO\u002FPGL or genetic pathogenic variants known to predispose individuals to develop these tumors.\n  * The presence of a tumor on conventional imaging including ultrasound, CT and\u002For MRI or \\[123I\\]-MIBG or PET imaging not limited to \\[18F\\]-FDG.\n* Children must give informed assent and be willing to return to the NIH for follow-up.\n\nExclusion criteria for research PET imaging in children:\n\n* Children of less than 10 years of age.\n* Children with impaired mental capacity that precludes informed assent.\n* Inability to lie still for the entire imaging time (e.g., cough, turbulent children, severe claustrophobia, etc.).","3 Years","120 Years",{"count":53,"type":21},3000,"INTERVENTIONAL",[56],"PHASE1","The goal of this study is to develop better methods of diagnosis, localization, and treatment for pheochromocytomas. These tumors, which usually arise from the adrenal glands, are often difficult to detect with current methods. Pheochromocytomas release chemicals called catecholamines, causing high blood pressure. Undetected, the tumors can lead to severe medical consequences, including stroke, heart attack and sudden death, in situations that would normally pose little or no risk, such as surgery, general anesthesia or childbirth.\n\nPatients with pheochromocytoma may be eligible for this study. Candidates will be screened with a medical history and physical examination, electrocardiogram, and blood and urine tests. Study participants will undergo blood, urine, and imaging tests, described below, to detect pheochromocytoma. If a tumor is found, the patient will be offered surgery. If surgery is not feasible (for example, if there are multiple tumors that cannot be removed), evaluations will continue in follow-up visits. If the tumor cannot be found, the patient will be offered medical treatment and efforts to detect the tumor will continue. Main diagnostic and research tests may include the following:\n\n1. Blood tests - mainly measurements of plasma or urine catecholamines and metanephrines as well as methoxytyramine. If necessary the clonidine suppression test can be carried out.\n2. Standard imaging tests - Non-investigational imaging tests include computed tomography (CT), magnetic resonance imaging (MRI), sonography, and 123I-MIBG scintigraphy and FDG (positron emission tomography) PET\u002FCT. These scans may be done before and\u002For after surgical removal of pheochromocytoma.\n3. Research PET scanning is done using an injection of radioactive compounds. Patients may undergo 18F-FDOPA, 18F-DA, as well as 68Ga-DOTATATE PET\u002FCT . Each scan takes up to about 2 hours.\n4. Genetic testing - A small blood sample is collected for DNA analysis and other analyses.",[59,25,60],"Pheochromocytoma","Endocrine Diseases",[62,63,64,65],"Genetics","Metanephrines","PET","Catecholamines","2026-06-17",{"date":68,"type":34},"2026-06-18",{"date":70,"type":34},"2000-03-22",{"date":72,"type":21},"2048-11-30",{"name":74,"class":41},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":22,"phases":4,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":42},"100632355","environment-inflammation-and-metabolic-diseases-study-100632355","NCT07512609","Environment, Inflammation and Metabolic Diseases Study","Inclusion Criteria:\n\n* All individuals who voluntarily participated in the physical examination\n\nExclusion Criteria:\n\nParticipants with incomplete data",true,{"count":83,"type":21},8000,"5 Years","The aim is to establish an effective and practical early warning model for endocrine and metabolic diseases based on an environmental-gene-protein panoramic network, to uncover new mechanisms underlying the onset and progression of these diseases, and to screen for novel therapeutic targets.",[25,87,88,89],"Metabolic Disorders","Hypertension","Diabetes Mellitus",[25,87,88,89],"2026-04-01",{"date":93,"type":34},"2026-04-06",{"date":95,"type":34},"2020-12-25",{"date":97,"type":21},"2026-12-31",{"name":99,"class":100},"Qifu Li","OTHER",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":42},"100620046","new-clinical-decision-support-score-based-on-steroid-hormone-profiling-in-the-diagnosis-of-macs-100620046","NCT07352527","New Clinical Decision Support Score Based on Steroid Hormone Profiling in the Diagnosis of MACS","New Clinical Decision Support Score Based on Steroid Hormone Profiling in the Diagnosis of Adrenal Adenomas With Moderate Autonomous Cortisol Secretion or MACS","MACSCORE","Inclusion Criteria:\n\nMACS and ANS group:\n\n* 18 years ≤ Age\n* Patient with one or more unilateral or bilateral adrenal nodules with spontaneous density \\\u003C 20 HU on CT and major axis ≥ 1 cm and without associated overt pathological hormonal secretion.\n* Patient with one or more uni or bilateral adrenal nodules not meeting the above density criteria but without malignancy criteria and stable in size on imaging after at least 6 months of follow-up and without associated overt pathological hormone secretion.\n* Written consent of the patient for his participation in the research (at the latest on the day of inclusion and before any examination required by the research).\n* Subject affiliated to or benefiting from a social security scheme.\n\nDiagnostic criteria (determined after blood sampling) for continuation of the study:\n\nMACS group:\n\n* At least two elevated DST1mg (Cortisol \\> 50 nmol\u002FL or 1.8 µg\u002FdL) AND\n* a plasma ACTH level ≤ 20 pg\u002FmL\n\nANS group:\n\n\\- Normal DST1mg (Cortisol ≤ 50 nmol\u002FL or 1.8 µg\u002FdL). The definition criteria for MACS and ANS were based on the latest recommandations of learned societies.\n\nControls group:\n\n* patients followed in the endocrinology department, free of any known adrenal pathology and with a DST1mg test \\\u003C 50nmol\u002FL.\n* matched for age and sex to patients in groups 1 and 2.\n\nNon -inclusion criteria:\n\n* Adrenal incidentaloma \\\u003C 1 cm in size.\n* Use of exogenous corticosteroids, whether systemic or local (inhaled, eye and ear drops, ophthalmic ointment, topical skin products, joint infiltration) in the 6 months prior to the trial, and drugs that interfere with the metabolism of dexamethasone.\n* Pregnant women.\n* Patients with any other life-threatening condition.\n* Patients with an intercurrent pathology at the time of blood sampling (fever, COVID infection, influenza....).\n* Urinary free cortisol (UFC) \\> at the limit of laboratory normality.\n* Patients under court protection.",{"count":110,"type":21},291,"The recent development of quantitative steroid metabolome profiling could be of interest for the positive diagnosis of mild autonomous cortisol-secreting adenoma (MACS). The aim of the study is to develop a predictive model of MACS status or non-secreting adenoma (NSA) based on a panel of 19 serum steroids and three clinico-biological parameters (body mass index or BMI, fasting glycaemia, blood pressure) and to estimate its performance for the diagnosis of MACS in a cohort of patients followed in the endocrinology department of Bordeaux University Hospital.",[25],[114,115,116,117],"Mild autonomous cortisol secreting adrenocortical adenoma","steroid hormone profiling","steroid metabolome","LC-MS\u002FMS","2026-01-13",{"date":120,"type":34},"2026-01-20",{"date":122,"type":34},"2025-11-19",{"date":124,"type":21},"2027-05",{"name":126,"class":100},"University Hospital, Bordeaux",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":42},"100289669","comprehensive-data-collection-and-follow-up-for-patients-with-thyroid-parathyroid-and-adrenal-disease-100289669","NCT03050762","Comprehensive Data Collection and Follow-Up for Patients With Thyroid, Parathyroid and Adrenal Disease","Inclusion Criteria:\n\n1. All patients that are being seen at MD Anderson with diagnosed or suspected endocrine disease. Patients will be selected from patients undergoing evaluation and\u002For treatment in the Endocrine Center, either by selection from a participating Endocrine physician or by screening from study personnel for patients scheduled to be seen in the Endocrine Clinic.\n2. In addition, we intend to contact family members of patients who are enrolled on the study, and found to be deceased at follow-up, to request permission to obtain cause of death, to determine whether cause of death may be related to endocrine disease.\n\nExclusion Criteria:\n\nN\u002FA",{"count":134,"type":21},15000,"The goal of this data review study is to collect data to learn more about thyroid, parathyroid, and adrenal disease.",[25],[25,138,139,140,141,142],"Thyroid disease","Parathyroid disease","Adrenal disease","Data Review","Database","2019-09-13",{"date":145,"type":34},"2019-09-17",{"date":147,"type":34},"2011-10-05",{"date":149,"type":21},"2027-10",{"name":151,"class":100},"M.D. Anderson Cancer Center"]